Pharsight

Varithena patents expiration

VARITHENA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7731986 PROVENSIS Therapeutic foam
Nov, 2024

(7 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6846412 PROVENSIS Combination filter assembly
Jul, 2022

(1 year, 8 months ago)

US8122917 PROVENSIS Apparatus and method for dispensing foam
Sep, 2024

(5 months from now)

US7814943 PROVENSIS Apparatus and method for dispensing foam
Nov, 2027

(3 years from now)

US9480652 PROVENSIS Aerosol valve
May, 2032

(8 years from now)

Varithena is owned by Provensis.

Varithena contains Polidocanol.

Varithena has a total of 5 drug patents out of which 1 drug patent has expired.

Expired drug patents of Varithena are:

  • US6846412

Varithena was authorised for market use on 25 November, 2013.

Varithena is available in solution;intravenous dosage forms.

Varithena can be used as a method of intravenous injection using ultrasound guidance, administered via a single cannula into the lumen of the target incompetent trunk veins or by direct injection into varicosities, a method of generating an injectable foam of controlled density and bubble size.

The generics of Varithena are possible to be released after 12 May, 2032.

Drugs and Companies using POLIDOCANOL ingredient

Market Authorisation Date: 25 November, 2013

Treatment: A method of generating an injectable foam of controlled density and bubble size; A method of intravenous injection using ultrasound guidance, administered via a single cannula into the lumen of the ta...

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

VARITHENA family patents

Family Patents